US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead programme, IB-T101, for clear cell renal cell carcinoma (ccRCC).
The trial will assess the therapy’s tolerability, preliminary efficacy and safety in ccRCC subjects who have relapsed on previous vascular endothelial growth factor targeting therapies with or without an immune checkpoint inhibitor.
Go deeper with GlobalData
Subjects will be enrolled across a dose-escalation phase to establish the therapy’s optimal dosage, with primary endpoints focusing on tolerability and safety, and secondary endpoints measuring pharmacokinetics and anti-tumour activity.
Inceptor Bio CEO Dr Matthias Schroff said: “This is a major milestone for Inceptor Bio as we advance IB-T101 into the clinic.
“With the support and confidence of our investors, we are focused on advancing our lead programme with the goal of delivering a best-in-class therapy that has the potential to change the treatment paradigm for patients facing these challenging cancers.”
IB-T101 is an autologous cluster of differentiation 70 CAR-T therapy that uses Inceptor Bio’s foundational platform, Outlast.
The Outlast programme reprogrammes T cells metabolically to enable them to survive the hostile tumour microenvironment.
Based in North Carolina, Inceptor Bio works to advance cell and gene therapies for curing cancer.
The company recently secured $21m in a Series A2 financing round led by Kineticos Life Sciences. It plans to use this funding to support both IB-T101’s development and the expansion of the company’s wider cell therapy pipeline.
Kineticos Life Sciences managing partner Shailesh Maingi said: “Dosing the first patient in a clinical trial is a significant milestone for any biotech company, and we are proud to support Inceptor Bio as they advance IB-T101 into the clinic.
“The OUTLAST platform represents a compelling approach to addressing key challenges in CAR-T therapy, and we believe this programme has the potential to make a real difference for patients with solid tumours.”
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
